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Mixing and matching mitochondrial
aminoacyl synthetases and their tRNAs:
a new way to treat respiratory
chain disorders?
Henna Tyynismaa1,2,* & Eric A. Schon3,4
Mutations in mitochondrial DNA are an
important cause of human disease and
from a therapeutic standpoint, these
disorders are currently untreatable. New
studies now show that a non-cognate mito-
chondrial aminoacyl tRNA synthetase can
overcome the respiratory defect caused by
an mt-tRNA mutation and that the isolated
carboxy-terminal domain of human mt-leu-
cyl tRNA synthetase can ameliorate the
pathologic phenotype.
See also: HT Hornig-Do et al (February 2014)
and E Perli et al (February 2014)
M utations in mitochondrial DNA(mtDNA) – a tiny circle encoding13 polypeptides, 2 rRNAs, and 22
tRNAs (Fig 1) – are an important cause of
human disease. The tRNA genes cover
<10% of the total 16.6-kb of human mtDNA,
yet about half of the known pathogenic
mutations are found in the tRNAs. Even
though most mutations in tRNAs affect mito-
chondrial translation, the resulting clinical
phenotypes are remarkably heterogeneous.
From a therapeutic standpoint, essentially
all of these disorders are currently untreat-
able, in part because attempts to correct
mutations in mtDNA in a stable and herita-
ble way have not yet succeeded. Thus,
creative alternative means to influence the
onset and progression of mtDNA-based dis-
eases are being investigated.
......................................................
“Even though most mutations
in tRNAs affect mitochondrial
translation, the resulting clini-
cal phenotypes are remarkably
heterogeneous.”
......................................................
Pathogenic mutations in mt-tRNAs typi-
cally interfere directly with cellular ATP pro-
duction, because the tRNAs are part of the
organellar translation system devoted to
the synthesis of the 13 subunits of the oxi-
dative phosphorylation (OXPHOS) com-
plexes that are encoded by mtDNA. Except
for the two ribosomal RNAs (also mtDNA-
encoded), all the other factors necessary
for mitochondrial protein synthesis are
encoded by nuclear genes and are
imported into mitochondria from the cyto-
plasm. These include the protein subunits
of the mitoribosome, translation elongation
factors, and the aminoacyl-tRNA syntheta-
ses (aaRSs). For most amino acids, the
cognate aaRS for each mitochondrial tRNA
is distinct from the counterpart tRNA syn-
thetase that functions in the cytoplasm.
Although aaRSs have the basic house-
keeping function of charging tRNAs with
their cognate amino acids in the initiation
step of protein synthesis, recent studies
have revealed unexpectedly versatile
“moonlighting” functions for many of the
cytoplasmic synthetases (Guo & Schimmel,
2013), in pathways ranging from angiogene-
sis to inflammation and apoptosis. Many of
these functions are performed by added
domains in the aaRS that are dispensable
for aminoacylation. For example, a C-termi-
nal “added” domain, UNE-S, in the cyto-
plasmic SerRS, is essential for vascular
development through directing SerRS to the
nucleus, where it regulates VEGF-A tran-
scription (Xu et al, 2012). Such domains
with “non-canonical” functions have not
been described previously for mammalian
mitochondrial aaRS’s, but a domain of the
mitochondrial leucyl-tRNA synthetase (mtL-
euRS) from S. cerevisiae has been shown to
have group I intron splicing activity (Labou-
esse, 1990). Importantly for mitochondrial
tRNA disease, this mtLeuRS domain was
shown to rescue mutants in yeast mt-tRNAs
equivalent to pathological mutations in the
corresponding human tRNA (Francisci et al,
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2011). In addition, several examples exist
where the expression level of the cognate
aaRS modulates the effect of the mitochon-
drial tRNA mutation, in both yeast and
human cell models: for example, mtLeuRS
suppressed a tRNALeu mutation in human
cells (Park et al, 2008) and a female with a
pathogenic tRNAIle mutation remained clini-
cally unaffected because she had a naturally
higher expression level of mtIleRS (Perli
et al, 2012). Another recent demonstration
of how aaRSs could influence the pene-
trance of mitochondrial diseases is the work
by Meiklejohn et al (2013) showing incom-
patibility of mtTyrRS and mt-tRNATyr geno-
types modulating mitochondrial protein
synthesis in Drosophila. It should also be
noted that the first reported mitochondrial
tRNA rescue was not by an aaRS, but by a
naturally-occurring structurally modified
tRNALeu(CUN) that suppressed a mutation in
tRNALeu(UUR) (El Meziane et al 1998).
......................................................
“Considering that there are no
rational treatments for mito-
chondrial tRNA diseases, a
universal suppressor molecule
for all tRNA mutations would
be an outstanding advance,
given, of course, all the caveats
that attend gene therapy-based
approaches to treating human
disease.”
......................................................
Inspired by the above-mentioned find-
ings, and as reported in this issue of EMBO
Molecular Medicine, Hornig-Do et al and
Perli et al have now tested the ability of a
human C-terminal mtLeuRS fragment to
rescue pathogenic tRNA mutations in human
patient-derived cytoplasmic hybrid (cybrid)
cell models. Their results show that the C-ter-
minal mtLeuRS can be imported in significant
amounts into mitochondria (although it lacks
a typical mitochondrial localization signal)
and is then sufficient to ameliorate the bioen-
ergetic defects of the cybrids. Importantly,
rescue by the C-terminal mtLeuRS was dem-
onstrated for the m.3243A>G mutation in
tRNALeu(UUR), which is associated with
MELAS (mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes), one
of the most common, and devastating,
mtDNA disorders (Perli et al, 2014).
While rescue of a tRNA mutation by its
cognate aaRS, by whatever mechanism (see
below), makes a certain amount of sense,
what is more surprising is the finding that
overexpression of an aaRS can ameliorate
dysfunction caused by mutations in non-cog-
nate tRNAs. The aaRSs are divided into two
classes (I and II), based on the architecture
of the active site (Ribas de Pouplana &
Schimmel, 2001). Hornig-Do et al provide
evidence that the C-terminal mtLeuRS (Class
I) binds to a number of mitochondrial
tRNAs, but the rescue effect on mutations
was demonstrated here only within Class I
(Fig 1). The studies focusing on pathogenic
mutations in tRNAIle, tRNALeu, and tRNAVal
and their cognate aaRSs showed interchange-
ability, but it should be noted that these
Class I aaRSs are particularly closely related.
The generalizability of the results for
the other Class I aaRSs and for Class II
aaRSs remains to be verified. Considering
that there are no rational treatments for
mitochondrial tRNA diseases, a universal
suppressor molecule for all tRNA mutations
would be an outstanding advance, given, of
course, all the caveats that attend gene
therapy-based approaches to treating human
disease.
The ability of the C-terminal mtLeuRS to
suppress functional defects caused by tRNA
mutations is intriguing, but the mechanism
of rescue is still controversial. Almost cer-
tainly it does not involve the aminoacylation
domain of the aaRS, since that region was
absent in the C-terminal fragment used by
both groups to rescue function. Rather, the
suspected RNA binding function of the
C-terminal domain of yeast mtLeuRS (Lab-
ouesse, 1990) suggests that it functions by
stabilizing the mutant tRNAs. Hornig-Do
et al show precisely that for the tRNAIle
mutation that they studied. The steady-state
levels of the uncharged mutant tRNA were
significantly lower in the untreated cybrid
line, and increased following the induction
of mtLeuRS C-term expression, leading to
enhanced mitochondrial translation, as
expected. On the other hand, Perli et al saw
no change in the levels of MELAS-mutant
tRNALeu after mtLeuRS C-term overexpres-
sion, although we note that this tRNA was
largely unstable to begin with. Taken
together, these results indicate that the
mechanism of rescue is more complicated
than simple general stabilization of the
tRNA, and depends on the specific tRNA and
mutation in question. For instance, the dif-
ferential post-transcriptional regulation of
tRNA levels could be a factor (King & Attar-
di, 1993). Considering the diverse effects
that the different tRNA mutations may have
on tRNA function - for example, the lack of
taurine modification at the anticodon
wobble position in tRNALeu(UUR) in MELAS
(Suzuki et al, 2002) – the C-term mtLeuRS
may in fact aid the mutant tRNAs in multiple
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Figure 1. Human mitochondrial DNA,
pathogenic tRNA mutations and
mitochondrial tRNA-synthetases used in the
rescue experiments. The human mitochondrial
DNA 16.6-kb genome encodes 7 subunits of
complex I (ND1, 2, 3, 4L, 4, 5, and 6), 1 subunit of
complex III (Cyt b), 3 subunits of complex IV
(COX1, 2, and 3), and 2 subunits of complex V (A6
and 8), as well as 2 rRNAs (12S and 16S) and 22
tRNAs (3-letter notation).
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ways. Clearly, development of optimal
treatment strategies will require a more pre-
cise understanding of the exact molecular
mechanisms of rescue.
Among the necessary future work is to
identify the minimal C-terminal fragment
that still retains both mitochondrial localiza-
tion and rescue ability, and to optimize the
delivery method. Delivery of a short peptide
could be ideal as a treatment, although obvi-
ous hurdles regarding pan-tissue delivery,
stability, and potential toxicity present them-
selves. Even if sufficient amounts of the pep-
tide were to enter the mitochondria, the
remainder will stay in the cytoplasm and it
is not yet clear whether it might interact
with any of the cytoplasmic tRNAs and
cause possible side effects. Unfortunately
mouse models of targeted mt-tRNA point
mutations are not available for testing,
because of our inability to directly manipu-
late the mammalian mitochondrial genome
in a stable and heritable way.
The importance of the mtLeuRS C-termi-
nus in understanding the basic biology of
mammalian mitochondria is also worth
investigating further – for example, does it
have an essential stabilizing function for
some or all mitochondrial tRNAs through
its RNA binding ability? Do other aaRS C-ter-
mini have a similar function? Do those from
Class I and Class II aaRS’s behave differ-
ently? Finally, mutations in many mitochon-
drial aaRSs themselves have recently been
found to cause mitochondrial diseases
(Konovalova & Tyynismaa, 2013). Perhaps
the C-terminal mtLeuRS could improve the
compromised tRNA stability in some of
these patients as well.
In summary, therapeutic options for
mitochondrial diseases are scarce and novel
ideas for treatment may arise from unex-
pected directions. Detailed work to under-
stand basic functions of mitochondria and
their evolution are the key to many discover-
ies. The mtLeuRS peptide is still far away
from the clinic, but its potential in treating
mitochondrial tRNA diseases is clearly wor-
thy of further investigation. The two papers
reported here are showing us the way.
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